Fig. 2From: Outcome differences between PD-1/PD-L1 inhibitors-based monotherapy and combination treatments in NSCLC with brain metastasesComparison of PFS and OS between patients with and without brain metastases. (A), Comparison of PFS between patients with and without brain metastases in all included patients; (B), Comparison of PFS between patients with and without brain metastases in patients received ICI based monotherapy; (C), Comparison of PFS between patients with and without brain metastases in patients received ICI based combination therapy; (D), Comparison of OS between patients with and without brain metastases in all included patients; (E), Comparison of OS between patients with and without brain metastases in patients received ICI based monotherapy; (F), Comparison of OS between patients with and without brain metastases in patients received ICI based combination therapy. BrM, brain metastasesBack to article page